6-溴喹唑啉-4-胺 | 21419-48-7

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-溴喹唑啉-4-胺
• 英文名称: 6-bromoquinazolin-4-amine
• 英文别名: 4-Amino-6-brom-chinazolin
• CAS: 21419-48-7
• 化学式: C₈H₆BrN₃
• mdl: MFCD02228849
• 分子量: 224.06
• InChiKey: FHCKWLXHKAPOBN-UHFFFAOYSA-N

物化性质

• 熔点：
  >350 °C
• 沸点：
  385.4±27.0 °C(Predicted)
• 密度：
  1.744±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光干燥密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromoquinazolin-4-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromoquinazolin-4-amine
CAS number: 21419-48-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6BrN3
Molecular weight: 224.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴喹唑啉-4-胺 在 potassium phosphate 、 二氯双[二叔丁基-(4-二甲基氨基苯基)膦]钯(II) 、 potassium acetate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 6-[2-(2-pyrrolidin-1-ylethylamino)-4-pyridyl]quinazolin-4-amine
  参考文献：
  名称：

  AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES

  摘要：

  这项发明提供了具有以下一般式的新化合物： 其中A，R1，R2和R3如本文所定义，包括这些化合物的组合物和使用这些化合物的方法。

  公开号：

  US20130324516A1
• 作为产物：
  描述：

  5-溴靛红酸酐 在 氨 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.25h， 以82%的产率得到6-溴喹唑啉-4-胺
  参考文献：
  名称：

  [EN] NOVEL CHEMICAL COMPOUNDS
  [FR] NOUVEAUX COMPOSES CHIMIQUES

  摘要：

  公开号：

  WO2007038331A3

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE<br/>[FR] INHIBITEURS À PETITE MOLÉCULE DE KINASE INDUISANT NF-KB
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020239999A1

  公开（公告）日：2020-12-03

  The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.

  本发明涉及抑制NIK的化合物，以及包含这些化合物的药物组合物和使用方法。这些化合物和药物组合物预期能用于预防或治疗癌症（如包括白血病、淋巴瘤和多发性骨髓瘤的B细胞恶性肿瘤）、炎症性疾病、自身免疫疾病、免疫皮肤病学疾病（如掌跖脓疱病和化脓性汗腺炎）以及代谢紊乱疾病（如肥胖和糖尿病）。
• Aryl nitrogen-containing bicyclic compounds and methods of use
  申请人：Patel F. Vinod

  公开号：US20070054916A1

  公开（公告）日：2007-03-08

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  这项发明涉及一类新的化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症、癌症和相关疾病。这些化合物具有一般的化学式I，其中A1、A2、A3、B、R1、R2、R3和R4在此有定义。因此，该发明还涉及包括该发明的化合物的药物组合物，使用该发明的化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备该发明的化合物的中间体和方法。
• An Organometallic Inhibitor for the Human Repair Enzyme 7,8-Dihydro-8-oxoguanosine Triphosphatase
  作者：Manuel Streib、Katja Kräling、Kristin Richter、Xiulan Xie、Holger Steuber、Eric Meggers

  DOI：10.1002/anie.201307849

  日期：2014.1.3

  small‐molecule inhibitor of the repair enzyme 8‐oxo‐dGTPase (MTH1) is presented, which is an unconventional cyclometalated ruthenium half‐sandwich complex. The organometallic inhibitor with low‐nanomolar activity displays astonishing specificity, as verified in tests with an extended panel of protein kinases and other ATP binding proteins. The binding of the organometallic inhibitor to MTH1 is investigated

  提出了基于探针发现修复酶 8-oxo-dGTPase (MTH1) 的第一个小分子抑制剂，这是一种非常规的环金属化钌半夹心复合物。具有低纳摩尔活性的有机金属抑制剂显示出惊人的特异性，这在一系列蛋白激酶和其他 ATP 结合蛋白的测试中得到证实。通过蛋白质晶体学研究有机金属抑制剂与 MTH1 的结合。
• [EN] GCN2 MODULATOR COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE GCN2
  申请人：BLACK BELT TX LTD

  公开号：WO2021165346A1

  公开（公告）日：2021-08-26

  The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein X, Y, R1, R2, R3, R4 and R5 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with General Control Nondepressible 2 (GCN2).

  本公开涉及式（1）的新化合物或其盐，其中X、Y、R1、R2、R3、R4和R5如本文所定义，并其在治疗、预防、改善、控制或减少与广泛控制不可抑制2（GCN2）相关的疾病风险中的用途。
• Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof
  申请人：REICH Melanie

  公开号：US20090069320A1

  公开（公告）日：2009-03-12

  Substituted 4-amino-quinazoline compounds corresponding to formula I methods for their production, pharmaceutical compositions containing these compounds as active agents, and the uses thereof for treating or inhibiting disorders or disease states.

  根据公式I的4-氨基喹唑啉化合物替代物，其生产方法，含有这些化合物的药物组合物以及用于治疗或抑制疾病状态或疾病状态的用途。